Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Core Insights - Avalo Therapeutics Inc. has completed enrollment for the Phase 2 LOTUS trial of its lead drug candidate AVTX-009, targeting approximately 250 adults with moderate to severe hidradenitis suppurativa, with topline data expected in mid-2026 [1] Group 1: Trial and Drug Information - The LOTUS trial will evaluate the efficacy and safety of bi-weekly and monthly dosing regimens of AVTX-009 compared to a placebo [1] - HiSCR75, a key measure for the trial, is defined as a 75% reduction in total abscess and inflammatory nodule count from baseline [3] Group 2: Analyst Insights - Cantor analyst Prakhar Agarwal notes that Avalo's stock could face a significant decline of 85-90% if the trial fails, but there is potential for stock upside if HiSCR75 change is around 18-19% [2] - If the HiSCR75 change is between 20-25%, the stock could rally by 100-150%, while a change of 25-30% could lead to a stock increase of over 200% [3] Group 3: Stock Performance and Ratings - Avalo's stock has underperformed compared to the SPDR S&P Biotech ETF, falling approximately 13% year-to-date, while the ETF has increased by 2% [4] - Recent analyst ratings have been positive, with Guggenheim initiating coverage with a target price of $50.00, and HC Wainwright maintaining a $25.00 target [5][6] - Mizuho has given an 'Outperform' rating with a $39.00 target, and BTIG reiterated a 'Buy' rating with a $40.00 target [6]